Previous entity Next entity
logo U1312 BRIC

U1312 BRIC

Team N°10 of BoRdeaux Institute of onCology (BRIC) INSERM unit 1312 “Normal and Leukemic Hematopoietic Stem Cells: persistence, signaling and therapeutic targets” brings together several researchers, biologists and physicians to develop a fundamental and translational research on acute myeloblastic leukemia (AML).

BRIC is a collective project with two main research themes: cancers with poor prognosis and rare cancers.

Image U1312 BRIC
Jean-max Pasquet
Dr. Jean-max Pasquet

Head of Entity

Contact

Email : jean-max.pasquet@u-bordeaux.fr

Université de Bordeaux
Bat BBS, 4ème étage, Bureau N.4035
2, rue du Dr Hoffmann Martinot
33000 BORDEAUX - France

Website

  • Acute Myeloid Leukemia (AML)

  • New oncogenic form of FLT3 receptor
  • Hematopoietic Stem Cell (HSC) fate regulation
  • Resistance and persistence of acute myeloid leukemic stem cells

  • Targeted therapy
  • Chemotherapy

Scientific

  • Preclinical development of different TKIs
  • Purging of leukemia-initiating cells by inhibition of autophagy and mobilization

Medical

  • Search for prognostic markers

 

  • Gilteritinib activity in refractory or relapsed FLT3-mutated acute myeloid leukemia patients previously treated by intensive chemotherapy and midostaurin: a study from the French AML Intergroup ALFA/FILO. Dumas PY, Raffoux E, Bérard E, Bertoli S, Hospital MA, Heiblig M, Desbrosses Y, Bonmati C, Pautas C, Lambert J, Orvain C, Banos A, Pasquier F, Peterlin P, Marchand T, Uzunov M, Frayfer J, Turlure P, Cluzeau T, Jourdan E, Himberlin C, Tavernier E, Villate A, Haiat S, Chretien ML, Carre M, Chantepie S, Vaida I, Wemeau M, Chebrek S, Guillerm G, Guièze R, Debarri H, Gehlkopf E, Laribi K, Marcais A, Santagostino A, Béné MC, Mineur A, Pigneux A, Dombret H, Récher C. Leukemia. 2023 Jan;37(1):91-101. doi: 10.1038/s41375-022-01742-7. 
  • Overlapping features of therapy-related and de novo NPM1-mutated AML. Othman J, Meggendorfer M, Tiacci E, Thiede C, Schlenk R, Dillon R, Stasik S, Venanzi A, Bertoli S, Delabesse E, Dumas PY, Pigneux A, Bidet A, Gilkes AF, Thomas I, Voso MT, Rambaldi A, Brunetti L, Perriello VM, Andresen V, Gjertsen BT, Martelli MP, Récher C, Röllig C, Bornhäuser M, Serve H, Müller-Tidow C, Baldus CD, Haferlach T, Russell N, Falini B. Blood. 2023 Apr 13;141(15):1846-1857. doi: 10.1182/blood. 
  • A scoring system for AML patients aged 70 years or older, eligible for intensive chemotherapy: a study based on a large European data set using the DATAML, SAL, and PETHEMA registries. Bérard E, Röllig C, Bertoli S, Pigneux A, Tavitian S, Kramer M, Serve H, Bornhäuser M, Platzbecker U, Müller-Tidow C, Baldus CD, Martínez-Cuadrón D, Serrano J, Martínez-Sánchez P, Arbolí ER, Gil C, Bergua J, Bernal T, de la Fuente Burguera A, Delabesse E, Bidet A, Dumas PY, Montesinos P, Récher C. Blood Cancer J. 2022 Jul 11;12(7):107. doi: 10.1038/s41408-022-00700-x. 
  • Protein Kinases in Leukemias. De Sepulveda P, Pasquet JM. Cancers (Basel). 2021 Jun 1;13(11):2747. doi: 10.3390/cancers13112747. 
  • Dual Inhibition of FLT3 and AXL by Gilteritinib Overcomes Hematopoietic Niche-Driven Resistance Mechanisms in FLT3-ITD Acute Myeloid Leukemia. Dumas PY, Villacreces A, Guitart AV, El-Habhab A, Massara L, Mansier O, Bidet A, Martineau D, Fernandez S, Leguay T, Pigneux A, Vigon I, Pasquet JM, Desplat V. Clin Cancer Res. 2021 Nov 1;27(21):6012-6025. doi: 10.1158/1078-0432.CCR-20-3114. Epub 2021 Aug 16. 
  • α-Tocopherol Acetate Attenuates Mitochondrial Oxygen Consumption and Maintains Primitive Cells within Mesenchymal Stromal Cell Population. Loncaric D, Rodriguez L, Debeissat C, Touya N, Labat V, Villacreces A, Bouzier-Sore AK, Pasquet JM, Brunet de la Grange P, Vlaski-Lafarge M, Pavlovic S, Ivanovic Z. Stem Cell Rev Rep. 2021 Aug;17(4):1390-1405. doi: 10.1007/s12015-020-10111-9. 
  • Downregulation of Glutamine Synthetase, not glutaminolysis, is responsible for glutamine addiction in Notch1-driven acute lymphoblastic leukemia. Nguyen TL, Nokin MJ, Terés S, Tomé M, Bodineau C, Galmar O, Pasquet JM, Rousseau B, van Liempd S, Falcon-Perez JM, Richard E, Muzotte E, Rezvani HR, Priault M, Bouchecareilh M, Redonnet-Vernhet I, Calvo J, Uzan B, Pflumio F, Fuentes P, Toribio ML, Khatib AM, Soubeyran P, Murdoch PDS, Durán RV. Mol Oncol. 2021 May;15(5):1412-1431. doi: 10.1002/1878-0261.12877. Epub 2021 Feb 13. 
  • Autophagy Targeting and Hematological Mobilization in FLT3-ITD Acute Myeloid Leukemia Decrease Repopulating Capacity and Relapse by Inducing Apoptosis of Committed Leukemic Cells. Dupont M, Huart M, Lauvinerie C, Bidet A, Guitart AV, Villacreces A, Vigon I, Desplat V, El Habhab A, Pigneux A, Ivanovic Z, Brunet De la Grange P, Dumas PY, Pasquet JM. Cancers (Basel). 2022 Jan 17;14(2):453. doi: 10.3390/cancers14020453. 
  • α-Tocopherol Attenuates Oxidative Phosphorylation of CD34+ Cells, Enhances Their G0 Phase Fraction and Promotes Hematopoietic Stem and Primitive Progenitor Cell Maintenance. Rodriguez L, Duchez P, Touya N, Debeissat C, Guitart AV, Pasquet JM, Vlaski-Lafarge M, Brunet de la Grange P, Ivanovic Z. Biomolecules. 2021 Apr 10;11(4):558. doi: 10.3390/biom11040558.

Research infrastructures

Cell culture facility

 

CellOxia (TBMCore service unit): tumor niche modeling

The platform offers equipment (XVivo Biosphérix) for carrying out experiments and/or incubating cells under controlled atmospheric conditions, to reproduce in vitro physiological or physiopathological parameters existing within a tissue. 

 

Biological samples

 

Various sources

AML

CRB-K authorisation AC-2019-3595, > 10,000 AML samples with consents and appended data.

 
Category Models Pathology Specification Sample type Number of models Genetics characterization
In vitro Human primary cells AML - Diagnosis - -
In vitro Human primary cells AML - Relapse - -
In vivo Mouse model AML AML Meis/HoxA9 - - -
In vivo Mouse model AML AML/AF9 - - -
In vivo PDX FLT3-ITD AML - - - All
Various sources 
Sample colection data		 DATAML Bordeaux CNIL 15.319 > 2,000 AML patients with consents.

Partnership research offers

LEUKEMIC NICHE MODELING (AML)

DEVELOPMENT OF NEW TARGETED THERAPIES FOR ACUTE MYELOID LEUKEMIA

Partners

Academics

Affiliation

Inserm Université de Bordeaux